Comparable stake leader
AGENUS INC
SEC ownership of MiNK Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001840229.
Disclosed value leader
AGENUS INC
Comparable rows
0/41
Latest evidence
11 Oct 2026
- Public ticker
- INKT on Nasdaq
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
AGENUS INC
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
11 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001840229
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of MiNK Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AGENUS INC
Disclosed value leader
AGENUS INC
Comparable rows
0/41
Latest evidence
11 Oct 2026
3/4/5
13F
Highest disclosed value: $22,643,778
41 rows are not safely comparable across share classes.
Showing 1-8 of 41 holder rows.
Quick read
AGENUS INC has the largest disclosed position value at $22.64M.
0 of 41 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AGENUS INC's linked filing trail.
Disclosed position value
Top 5
AGENUS INC
$22.64M
Garo H. Armen
$2.05M
VANGUARD CAPITAL MANAGEMENT LLC
$802.6K
Jennifer Buell
$783.5K
DnB Asset Management AS
$644.6K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 41 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AGENUS INC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$22,643,778
21,772,863 shares
|
— | 12 Oct 2023 |
| Garo H. Armen |
3/4/5
Director
|
—
denominator unverified
|
$2,045,056
1,966,400 shares
|
— | 05 May 2023 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$802,635
68,660 shares
|
— | 30 Jun 2026 |
| Jennifer Buell |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$783,499
170,577 shares
mixed-class rows
|
-$73,265 | 11 Oct 2026 |
| DnB Asset Management AS |
13F
Company
|
—
denominator unverified
|
$644,610
55,142 shares
|
— | 30 Jun 2026 |
| Brian Corvese |
3/4/5
Director
|
—
mixed-class rows
|
$640,261
60,165 shares
mixed-class rows
|
— | 01 Sep 2026 |
| Ulf Wiinberg |
3/4/5
Director
|
—
mixed-class rows
|
$605,062
57,154 shares
mixed-class rows
|
— | 01 Sep 2026 |
| Peter Behner |
3/4/5
Director
|
—
mixed-class rows
|
$285,282
29,799 shares
mixed-class rows
|
— | 01 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$119,884.
Buys
$0
Insiders: 0
Sells
$119,884
Insiders: 2
Net
-$119,884
Shares: -10,438
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 10,438
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 6,938 | $0 | $73,265 | -$73,265 |
| 3-6 | 0 | 1,500 | $0 | $19,141 | -$19,141 |
| 6-9 | 0 | 2,000 | $0 | $27,478 | -$27,478 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to MiNK Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
AGENUS INC
Net 12M change
-$119,884
Latest report
11 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| AGENUS INC | 10%+ Owner | $22,643,778 | Mixed | 12 Oct 2023 | ||
| Garo H. Armen | Director | $2,045,056 | Mixed | 05 May 2023 | ||
| Jennifer Buell | Chief Executive Officer, Director | $783,499 | -$73,265 | -8.6% | Filing P/S | 11 Oct 2026 |
| Brian Corvese | Director | $640,261 | Mixed | 01 Sep 2026 | ||
| Ulf Wiinberg | Director | $605,062 | Mixed | 01 Sep 2026 | ||
| Peter Behner | Director | $285,282 | Mixed | 01 Sep 2026 | ||
| Barbara Ryan | Director | $275,778 | -$46,619 | -14% | Mixed | 01 Sep 2026 |
| Robert Peter Kadlec | Director | $212,107 | Mixed | 01 Dec 2025 | ||
| Christine M. Klaskin | Treasurer | $57,886 | Mixed | 13 Oct 2021 | ||
| John Bradley Holcomb | Director | $54,837 | Mixed | 01 Sep 2026 | ||
| John Baldoni | Director | $42,841 | Mixed | 01 Sep 2023 | ||
| Melissa Orilall | Principal Financial Officer | $2,282 | Mixed | 13 Mar 2026 | ||
| Austin Charette | Principal Accounting Officer | $441 | Mixed | 13 Mar 2026 | ||
| Marc Antonius van Dijk | Chief Scientific Officer | Mixed | 16 Jan 2024 | |||
| Walter Flamenbaum MD | Director | Mixed | 13 Oct 2021 |
Recent insider transactions for MiNK Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer Buell | INKT | Common Stock | Sale | -8.55% | $73,265 | $10.56 | -6,938 | 74,195 | 12 Oct 2026 | Direct |
| Jennifer Buell | INKT | Common Stock | Options Exercise | 40% | 23,191 | 81,133 | 11 Oct 2026 | Direct | ||
| Jennifer Buell | INKT | Restricted Stock Units | Options Exercise | -33.3% | -23,191 | 46,382 | 11 Oct 2026 | Direct | ||
| Ulf Wiinberg | INKT | Common Stock | Award | 5.65% | 1,279 | 23,929 | 01 Sep 2026 | Direct | ||
| John Bradley Holcomb | INKT | Common Stock | Award | 35.7% | 1,233 | 4,691 | 01 Sep 2026 | Direct | ||
| Peter Behner | INKT | Common Stock | Award | 6.48% | 1,485 | 24,404 | 01 Sep 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Award | 7.38% | 1,622 | 23,591 | 01 Sep 2026 | Direct | ||
| Brian Corvese | INKT | Common Stock | Award | 3.07% | 1,633 | 54,770 | 01 Sep 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Sale | -6.39% | $19,141 | $12.76 | -1,500 | 21,969 | 04 Jun 2026 | Direct |
| John Bradley Holcomb | INKT | Common Stock | Award | 46.1% | 1,091 | 3,458 | 01 Jun 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Award | 6.51% | 1,434 | 23,469 | 01 Jun 2026 | Direct | ||
| Brian Corvese | INKT | Common Stock | Award | 2.79% | 1,444 | 53,137 | 01 Jun 2026 | Direct | ||
| Peter Behner | INKT | Common Stock | Award | 6.08% | 1,313 | 22,919 | 01 Jun 2026 | Direct | ||
| Ulf Wiinberg | INKT | Common Stock | Award | 5.26% | 1,131 | 22,650 | 01 Jun 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Sale | -5.99% | $20,017 | $15.40 | -1,300 | 20,406 | 10 Mar 2026 | Direct |
| Barbara Ryan | INKT | Common Stock | Sale | -0.91% | $2,034 | $10.17 | -200 | 21,706 | 09 Mar 2026 | Direct |
| John Bradley Holcomb | INKT | Common Stock | Award | 109.8% | 1,239 | 2,367 | 02 Mar 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Award | 7.98% | 1,629 | 22,035 | 02 Mar 2026 | Direct | ||
| Brian Corvese | INKT | Common Stock | Award | 3.28% | 1,640 | 51,693 | 02 Mar 2026 | Direct | ||
| Peter Behner | INKT | Common Stock | Award | 7.41% | 1,491 | 21,606 | 02 Mar 2026 | Direct | ||
| Ulf Wiinberg | INKT | Common Stock | Award | 6.35% | 1,285 | 21,519 | 02 Mar 2026 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Sale | -0.45% | $1,083 | $10.83 | -100 | 21,906 | 02 Mar 2026 | Direct |
| Barbara Ryan | INKT | Common Stock | Sale | -1.79% | $4,343 | $10.86 | -400 | 22,006 | 27 Feb 2026 | Direct |
| Jennifer Buell | INKT | Common Stock | Tax liability | -14.8% | -10,024 | 57,942 | 02 Jan 2026 | Direct | ||
| Ulf Wiinberg | INKT | Stock Option (Right to Buy) | Award | 5,395 | 5,395 | 02 Jan 2026 | Direct | |||
| Barbara Ryan | INKT | Stock Option (Right to Buy) | Award | 5,395 | 5,395 | 02 Jan 2026 | Direct | |||
| Brian Corvese | INKT | Stock Option (Right to Buy) | Award | 5,395 | 5,395 | 02 Jan 2026 | Direct | |||
| Peter Behner | INKT | Stock Option (Right to Buy) | Award | 5,395 | 5,395 | 02 Jan 2026 | Direct | |||
| Brian Corvese | INKT | Common Stock | Award | 3.33% | 1,612 | 50,053 | 01 Dec 2025 | Direct | ||
| Peter Behner | INKT | Common Stock | Award | 7.86% | 1,466 | 20,115 | 01 Dec 2025 | Direct | ||
| Barbara Ryan | INKT | Common Stock | Award | 7.7% | 1,601 | 22,406 | 01 Dec 2025 | Direct | ||
| John Bradley Holcomb | INKT | Common Stock | Award | 1,128 | 1,128 | 01 Dec 2025 | Direct | |||
| Robert Peter Kadlec | INKT | Common Stock | Award | 6.8% | 1,218 | 19,126 | 01 Dec 2025 | Direct | ||
| Ulf Wiinberg | INKT | Common Stock | Award | 6.66% | 1,263 | 20,234 | 01 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.